Capricor Posts Wider Q3 Loss of 73 Cents, Zero Revenue vs $41.7M Expected
CAPR has more than doubled off its 52-week low of $2.96.
Summary
Capricor reported a Q3 adjusted loss of 73 cents a share, well wider than the 43-cent consensus and worse than last year's 54-cent loss. Revenue came in at zero against analyst expectations of $41.71 million, and the net loss was $42.66 million. Cash fell to $198.5 million from $318.1 million at year-end, per the 8-K filed tonight, extending the burn pattern from Q2's $237.9 million. This is the fourth straight quarterly miss and the estimate trend has deteriorated sharply, with the mean loss estimate down about 133.5% over three months. The real driver remains the deramiocel BLA, with the FDA's PDUFA action date set for November 22, 2026 — twelve days out.
At the time of this announcement, CAPR was trading at $9.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $515.7M. The 52-week trading range was $2.96 to $40.37. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.